Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026

Pacira Biosciences, Inc. (PCRX)

A forensic read on Pacira Biosciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

C · Mixed — selective

Forensic grade

Safe

Financial health

3.6

Distress distance

Clean

Earnings quality

Forensic signals

196.8

P / E (ttm)

1.0%

ROE

$976M

Market cap

3.6%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Pacira Biosciences, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 3.6, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by inventory days.

What the filings flag

339d

FY2024→FY2025

Inventory days. Days inventory outstanding moved from 246 to 339 FY2024→FY2025 (against cost of goods sold; inventory +22% vs -12% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.

1.3%

FY2025

Return on invested capital. Return on invested capital is 1.3% in the latest fiscal year and slipping from 4% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.

109% of FCF

FY2025

Shareholder returns. Returned $148M to shareholders (buybacks + dividends) in FY2025 — 109% of free cash flow. Right at the limit of what free cash flow covers — little room before it's funded by debt or the balance sheet. That ratio has been CLIMBING toward the limit — 0% of free cash flow a few years back — not just sitting there. Counting the $58M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 151%.

$163M

FY2024–FY2024

Goodwill impairments. Took $163M of goodwill writedowns across 1 year (FY2024 ($163M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$726.4M

Revenue Growth YoY+3.6%

Revenue CAGR (3yr)+2.9%

Net Margin1.0%

Free Cash Flow$136.7M

Return on Equity1.0%

Debt / Equity0.54x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Pacira Biosciences, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.